Richard L Wahl

Q: What Schools Are Affiliated With Richard L Wahl

Richard L Wahl is affiliated with the following schools: Washington University in St. Louis, University of California, Berkeley, Mallinckrodt Institute of Radiology, University of Michigan, Hannover Medical School, Stanford University, Johns Hopkins University

Richard L Wahl's AcademicInfluence.com Rankings

Richard L Wahl

Engineering

#2109

World Rank

#2956

Historical Rank

Electrical Engineering

#342

World Rank

#386

Historical Rank

engineering Degrees

Richard L Wahl

Computer Science

#3043

World Rank

#3191

Historical Rank

Computational Linguistics

#107

World Rank

#109

Historical Rank

Machine Learning

#280

World Rank

#283

Historical Rank

Artificial Intelligence

#454

World Rank

#461

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Richard L Wahl's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley
Bachelors Computer Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2025

Why Is Richard L Wahl Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard L Wahl's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors (2009) (3116)
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. (2005) (1736)
Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. (1999) (826)
Recommendations on the Use of 18F-FDG PET in Oncology (2008) (766)
131I-tositumomab therapy as initial treatment for follicular lymphoma. (2005) (699)
Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. (1999) (684)
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. (1993) (646)
Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. (1993) (615)
Dynamic Imaging of Allogeneic Mesenchymal Stem Cells Trafficking to Myocardial Infarction (2005) (582)
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. (2001) (576)
Overexpression of glut‐1 glucose transporter in human breast cancer an immunohistochemical study (1993) (566)
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. (2000) (533)
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations (1997) (530)
Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. (1994) (445)
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. (2006) (428)
Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. (1991) (426)
Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. (2003) (426)
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. (1996) (417)
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. (1996) (389)
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. (2000) (360)
Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. (1993) (344)
Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. (2004) (330)
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. (2006) (330)
Metrology Standards for Quantitative Imaging Biomarkers. (2015) (303)
Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. (1995) (301)
Direct Comparison of 18F-FDG PET and PET/CT in Patients with Colorectal Carcinoma (2003) (285)
Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. (1994) (282)
"USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. (2003) (282)
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. (2016) (278)
Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. (1995) (272)
Detection of unexpected additional primary malignancies with PET/CT. (2005) (272)
Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. (1996) (271)
Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. (2003) (266)
Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results (1998) (262)
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. (2009) (262)
Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. (1999) (261)
Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment (2015) (259)
Improved radioimaging and tumor localization with monoclonal F(ab')2. (1983) (258)
"Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. (1993) (251)
Normal FDG distribution patterns in the head and neck: PET/CT evaluation. (2005) (250)
Bacteriolytic therapy can generate a potent immune response against experimental tumors. (2004) (250)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. (2005) (246)
Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases (2017) (243)
Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT (2003) (239)
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. (1999) (237)
111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction (2003) (220)
Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. (2003) (219)
Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. (1992) (212)
18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography (1991) (206)
Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value (2012) (206)
Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans. (2016) (202)
Evaluation of FDG PET in patients with cervical cancer. (1999) (196)
Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. (2003) (192)
Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. (1998) (190)
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma (2017) (181)
Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. (1993) (177)
Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. (2003) (172)
Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. (2004) (168)
Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. (2008) (166)
PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. (2002) (166)
Improved Staging With Pretreatment Positron Emission Tomography/Computed Tomography in Low Rectal Cancer (2006) (165)
Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. (2004) (160)
CT Hounsfield Units of Brown Adipose Tissue Increase with Activation: Preclinical and Clinical Studies (2010) (159)
Initial experience with oral contrast in PET/CT: phantom and clinical studies. (2003) (158)
In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. (1995) (158)
Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application (2013) (155)
PET-CT: accuracy of PET and CT spatial registration of lung lesions (2003) (151)
Initial experience with FDG-PET/CT in the evaluation of breast cancer (2006) (151)
In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. (1993) (151)
Expression of hexokinase II and Glut-1 in untreated human breast cancer. (2002) (146)
Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. (1996) (145)
Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG) (2001) (144)
Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria)—Interreader Reliability, Accuracy, and Survival Outcomes (2014) (143)
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. (2007) (141)
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy (2004) (140)
Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. (2004) (139)
Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? (1995) (139)
Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. (2005) (137)
Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. (2005) (136)
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. (1998) (136)
18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy* (2009) (135)
Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging–Based Internal Dosimetry (2007) (135)
Exposure to strong static magnetic field slows the growth of human cancer cells in vitro. (1996) (133)
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. (2009) (132)
Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, l-methionine, 67Ga-citrate, and 125I-HSA (1999) (132)
The Role of Positron Emission Tomography/Computed Tomography in the Management of Recurrent Papillary Thyroid Carcinoma (2005) (128)
Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. (2009) (126)
Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. (2003) (125)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. (1993) (124)
Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. (1998) (123)
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. (2009) (121)
Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. (1998) (120)
Sentinel node localization in oral cavity and oropharynx squamous cell cancer. (2001) (120)
Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. (2003) (120)
Preliminary assessment of fluorine-18 fluorodeoxyglucose positron mission tomography in patients with bladder cancer (1997) (118)
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. (2003) (114)
Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. (1999) (111)
Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. (2002) (106)
Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. (1998) (105)
Dynamic whole-body PET imaging: principles, potentials and applications (2018) (103)
Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. (2005) (102)
Principles and Practice of Positron Emission Tomography (2002) (100)
New methods for imaging the breast: techniques, findings, and potential. (1995) (100)
Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey (2011) (97)
CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. (2005) (97)
Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging (2014) (97)
Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. (1992) (96)
The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. (2006) (96)
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. (2007) (94)
FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers (2003) (94)
Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT (2007) (94)
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice (2007) (93)
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. (1998) (92)
CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. (1994) (92)
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials (2015) (92)
Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS (2004) (91)
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. (2009) (91)
Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. (1996) (91)
PET-CT in recurrent ovarian cancer: initial observations. (2004) (90)
Prevalence and Patterns of Bone Metastases Detected with Positron Emission Tomography Using F-18 FDG (2003) (90)
Quantitative Imaging in Cancer Clinical Trials (2016) (90)
Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. (1979) (89)
Clinical use of positron emission tomography in the management of cutaneous melanoma. (2004) (88)
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. (2011) (88)
Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. (1995) (87)
Bone marrow cell trafficking following intravenous administration (1999) (87)
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. (2005) (87)
Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. (1999) (86)
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. (2003) (86)
PET-CT detection of abdominal recurrence of ovarian cancer: radiologic–surgical correlation (2004) (85)
Promise and pitfalls of quantitative imaging in oncology clinical trials. (2012) (83)
Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. (2003) (83)
Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. (1998) (83)
Three-dimensional imaging-based radiobiological dosimetry. (2008) (82)
Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy (2007) (81)
Current status of PET in breast cancer imaging, staging, and therapy. (2001) (81)
Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT. (2006) (80)
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. (2005) (79)
Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation (2013) (79)
Incremental value of CT in PET/CT of patients with colorectal carcinoma (2004) (79)
Chemotherapy and Chemoprevention by Thiazolidinediones (2015) (79)
Absolute myocardial flow quantification with 82Rb PET/CT: comparison of different software packages and methods (2013) (77)
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. (2014) (77)
Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. (1991) (75)
124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison (2009) (75)
Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. (2006) (74)
Microbiota and Thyroid Interaction in Health and Disease (2019) (74)
Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. (2005) (73)
Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer (2011) (72)
Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy (2009) (72)
Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. (1992) (69)
Prediction of the Need for Surgical Intervention in Obstructive Crohn's Disease by 18F-FDG PET/CT (2009) (69)
Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. (2008) (69)
The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. (1990) (69)
The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy (2013) (69)
Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET (2015) (69)
Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT (2003) (68)
Myocardial substrate and route of administration determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells (2011) (67)
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial (2017) (67)
FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma: Characteristics of Human Papillomavirus–Positive and –Negative Tumors (2014) (66)
Effect of Nicotine and Ephedrine on the Accumulation of 18F-FDG in Brown Adipose Tissue (2007) (65)
Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. (2002) (65)
Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study (1999) (65)
Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET. (1995) (63)
To AC or not to AC: that is the question. (1999) (63)
Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. (1993) (63)
Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. (1996) (63)
Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. (2009) (62)
Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. (1997) (62)
Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. (2000) (62)
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. (2002) (62)
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. (2003) (61)
Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. (1991) (60)
Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. (2006) (60)
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma (2008) (59)
TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer (2015) (58)
Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positron-sensitive probe: validation in preclinical studies. (1995) (58)
The Relationship between Patients’ Serum Glucose Levels and Metabolically Active Brown Adipose Tissue Detected by PET/CT (2011) (58)
Study of the Impact of Tissue Density Heterogeneities on 3-Dimensional Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo Methods (2013) (58)
Simultaneous usage of homologous points, lines, and planes for optimal, 3-D, linear registration of multimodality imaging data (1995) (57)
Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. (1994) (57)
Principles and practice of PET and PET/CT (2013) (57)
FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT. (1998) (56)
Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma. (2000) (56)
Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. (2006) (56)
Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. (2009) (56)
Comparison of Uptake of Multiple Clinical Radiotracers into Brown Adipose Tissue Under Cold-Stimulated and Nonstimulated Conditions (2007) (55)
The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. (2014) (55)
Utility of lymphoscintigraphy in directing surgical therapy for melanomas of the head, neck, and upper thorax. (1987) (54)
18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy (2008) (54)
Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning—Monte Carlo Simulation Studies (2008) (54)
The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. (2011) (54)
Hyaluronic acid-human blood hydrogels for stem cell transplantation. (2012) (54)
PET/CT: artifacts caused by bowel motion (2004) (54)
Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. (1996) (54)
Quantitative Imaging and Sigmoidoscopy to Assess Distribution of Rectal Microbicide Surrogates (2008) (53)
Relationship of Delayed Enhancement by Magnetic Resonance to Myocardial Perfusion by Positron Emission Tomography in Hypertrophic Cardiomyopathy (2013) (53)
Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer (2011) (52)
Diagnosis and Differentiation of Bronchioloalveolar Carcinoma from Adenocarcinoma with Bronchioloalveolar Components with Metabolic and Anatomic Characteristics Using PET/CT (2008) (51)
Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. (2006) (50)
Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. (2000) (50)
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. (2005) (50)
Quantitative assessment of myocardial blood flow--clinical and research applications. (2014) (50)
18F-FDG PET/CT Qualitative and Quantitative Evaluation in Neurofibromatosis Type 1 Patients for Detection of Malignant Transformation: Comparison of Early to Delayed Imaging With and Without Liver Activity Normalization (2015) (49)
Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. (2014) (49)
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. (2006) (48)
Semi-quantitative ventilation/perfusion scintigraphy and single-photon emission tomography for evaluation of lung volume reduction surgery candidates: description and prediction of clinical outcome (1999) (48)
Clinically significant abnormal findings on the "nondiagnostic" CT portion of low-amperage-CT attenuation-corrected myocardial perfusion SPECT/CT studies. (2006) (48)
Iodine-125-MIBG to treat neuroblastoma: preliminary report. (1990) (47)
Tositumomab and 131I Therapy in Non-Hodgkin’s Lymphoma (2005) (47)
Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. (2014) (47)
Follow-up or Surveillance 18F-FDG PET/CT and Survival Outcome in Lung Cancer Patients (2014) (47)
18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies (2003) (47)
A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. (2011) (46)
Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum. (1992) (46)
18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies (2007) (46)
Morphine-augmented hepatobiliary scintigraphy in the severely ill: caution is in order. (1990) (45)
Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET (2002) (45)
Molecular imaging in thyroid cancer (2010) (45)
Sacral fractures: a potential pitfall of FDG positron emission tomography. (2003) (44)
Cardiac PET/CT Misregistration Causes Significant Changes in Estimated Myocardial Blood Flow (2013) (44)
PET/CT Assessment of Symptomatic Individuals with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (2012) (44)
PET-CT evaluation of 2-deoxy-2-[18F]fluoro-D-glucose myocardial uptake: effect of respiratory motion. (2003) (43)
Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. (1999) (42)
Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. (1998) (42)
Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer. (1999) (42)
Visualization of Brown Adipose Tissue with 99mTc-Methoxyisobutylisonitrile on SPECT/CT (2008) (42)
A fiber-optically coupled positron-sensitive surgical probe. (1994) (41)
Radionuclide imaging metabolic activity of brown adipose tissue in a patient with pheochromocytoma. (2004) (41)
Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. (1990) (41)
Uptake of 2-deoxy-2-[18F]fluoro-d-glucose in the normal testis: Retrospective PET study and animal experiment (1997) (41)
Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. (2012) (40)
Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry (2014) (40)
Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose. (1991) (39)
Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma (2012) (39)
Reproducibility of Tumor Blood Flow Quantification with 15O-Water PET (2008) (39)
18F-FDG PET/CT Radiomic Analysis with Machine Learning for Identifying Bone Marrow Involvement in the Patients with Suspected Relapsed Acute Leukemia (2019) (39)
18F-Fluorobenzyl Triphenyl Phosphonium: A Noninvasive Sensor of Brown Adipose Tissue Thermogenesis (2011) (39)
Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of U.S. Medical Oncologists and Hematologists (2010) (39)
Immunoglobulin-complexed aspartate aminotransferase. (1983) (38)
Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. (1990) (38)
Addition of 18F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years (2013) (38)
Non‐invasive methods for the assessment of brown adipose tissue in humans (2018) (37)
The forgotten effects of thyrotropin-releasing hormone: metabolic functions and medical applications (2018) (37)
Comparison of mutual information-based warping accuracy for fusing body CT and PET by 2 methods: CT mapped onto PET emission scan versus CT mapped onto PET transmission scan. (2002) (37)
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer (2009) (37)
Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. (1997) (37)
Atlas of Clinical Positron Emission Tomography (1999) (37)
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. (2009) (37)
The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. (2020) (36)
Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine‐131 tositumomab therapy (2002) (35)
Simultaneous measurement of noise and spatial resolution in PET phantom images (2010) (35)
Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists (2011) (35)
Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study (2008) (35)
Regional 2-[18F]fluoro-2-deoxy-d-glucose uptake varies in normal lung (2004) (35)
Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. (2007) (34)
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas (2017) (34)
Radiology of colorectal cancer. (2002) (33)
Diabetes Decreases FDG Accumulation in Primary Lung Cancer. (1999) (33)
Phosphorus-32 therapy of cystic Grade IV astrocytomas: technique and preliminary application. (1985) (33)
Advantages of Hybrid SPECT/CT vs SPECT Alone (2008) (33)
Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. (2008) (33)
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer (2021) (32)
Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat. (1991) (32)
Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans. (1996) (32)
Applications of PET in liver imaging. (2005) (31)
The effect of regadenoson on the integrity of the human blood–brain barrier, a pilot study (2017) (31)
Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies. (2000) (31)
Dynamic Multi-Bed FDG PET imaging: Feasibility and optimization (2011) (31)
Responses of the Insulin Signaling Pathways in the Brown Adipose Tissue of Rats following Cold Exposure (2014) (31)
Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. (2012) (30)
Use of 2-[F-18]-fluoro-2-deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. (1994) (30)
Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab (2010) (30)
How Reproducible Is Bioluminescent Imaging of Tumor Cell Growth? Single Time Point versus the Dynamic Measurement Approach (2007) (30)
Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. (2003) (30)
Proceedings of a National Cancer Institute workshop: PET in oncology--a clinical research agenda. (1994) (30)
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. (2019) (29)
Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma (2017) (29)
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0 (2022) (29)
Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT (2006) (28)
Hyaluronic acid-serum hydrogels rapidly restore metabolism of encapsulated stem cells and promote engraftment. (2015) (28)
A Practical, Automated Quality Assurance Method for Measuring Spatial Resolution in PET (2009) (28)
In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab (2008) (28)
Bone metastases in pheochromocytoma: comparative studies of efficacy of imaging. (1986) (28)
Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results. (2009) (28)
Does the FDG Uptake of Primary Non-Small Cell Lung Cancer Predict Prognosis?. A Work in Progress. (1999) (28)
Comprehensive Radionuclide Esophagogastrointestinal Transit Study: Methodology, Reference Values, and Initial Clinical Experience (2015) (28)
The Need for Better Methods to Determine Release Criteria for Patients Administered Radioactive Material (1998) (28)
Sulfhydryl site-specific cross-linking and labeling of monoclonal antibodies by a fluorescent equilibrium transfer alkylation cross-link reagent. (1990) (27)
The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage (2004) (27)
FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. (2018) (27)
Choosing an optimal radioimmunotherapy dose for clinical response (2002) (27)
Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. (2016) (27)
Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. (2018) (27)
Influence of thyroid hormones and catecholamines on myosin of swim-exercised rats. (1990) (27)
Spatiotemporal distribution modeling of PET tracer uptake in solid tumors (2017) (26)
Novel multi-parametric SUV/Patlak FDG-PET whole-body imaging framework for routine application to clinical oncology (2015) (26)
Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data (2014) (26)
Evaluation of ion-implanted-silicon detectors for use in intraoperative positron-sensitive probes. (1996) (26)
Products of cells cultured from gliomas. VI. Immunofluorescent, morphometric, and ultrastructural characterization of two different cell types growing from explants of human gliomas. (1987) (25)
PET Scanning and Measuring the Impact of Treatment (2002) (25)
Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks (2018) (25)
Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. (2012) (25)
Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry and 18F-FDG PET/CT (2018) (25)
Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. (1998) (24)
PERCIST in Perspective (2018) (24)
On-Call Radiology Resident Discrepancies: Categorization by Patient Location and Severity. (2016) (24)
Tumor response assessment is more robust with sequential CT scanning than external caliper measurements. (2005) (23)
18F-FDG PET/CT and Lung Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management (2015) (23)
Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL). (2004) (23)
The influence of monoclonal antibody dose on tumor uptake of radiolabeled antibody. (1986) (23)
Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. (2001) (23)
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts (2018) (23)
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines (2009) (23)
Urinary iodine: comparison of a simple method for its determination in microplates with measurement by inductively-coupled plasma mass spectrometry (2017) (22)
Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO) (2019) (22)
Animal studies on the reduction and/or dilution of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) activity in the urinary system (1997) (22)
Direct 4D whole-body PET/CT parametric image reconstruction: Concept and comparison vs. indirect parametric imaging (2013) (22)
Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach. (2018) (22)
AI-based methods for nuclear-medicine imaging: Need for objective task-specific evaluation (2020) (22)
Effect of Patient Arm Motion in Whole-Body PET/CT (2011) (22)
Quantitative whole-body parametric PET imaging incorporating a generalized Patlak model (2013) (22)
Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor (2016) (22)
Measurement Repeatability of 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Solid Tumors of the Pelvis (2019) (22)
Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy. (2012) (22)
Scalene muscle uptake: a potential pitfall in head and neck PET/CT (2007) (21)
Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development (2021) (21)
Performance assessment of a NaI(Tl) gamma counter for PET applications with methods for improved quantitative accuracy and greater standardization (2015) (21)
Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications (2009) (20)
FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy (2004) (20)
Liver Standardized Uptake Value Corrected for Lean Body Mass at FDG PET/CT: Effect of FDG Uptake Time (2015) (20)
Reproducibility of lymphoscintigraphic drainage patterns in sequential 99mTc human serum albumin and 99mTc sulfur colloid studies: implications for sentinel node identification in melanoma. (1999) (20)
Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms (2016) (20)
Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma (2013) (20)
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC (2017) (19)
Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts (2013) (19)
Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with 18F-Fluorodeoxyglucose in Humans. (2019) (19)
Delayed biliary drainage is common in asymptomatic post-cholecystectomy volunteers. (1992) (19)
Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET (1997) (18)
Assessment of Tumoricidal Efficacy and Response to Treatment with 18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor (2011) (18)
Dot-based ELISA and RIA: two rapid assays that screen hybridoma supernatants against whole live cells. (1984) (18)
Radioimmunodiagnosis of human-derived squamous cell carcinoma. (1987) (18)
Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma (2011) (18)
A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck (2012) (17)
F-18 FDG PET/CT in Acute Respiratory Distress Syndrome: A Case Report (2004) (17)
Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. (1997) (17)
A Multisite Study of a Breast Density Deep Learning Model for Full-Field Digital Mammography and Synthetic Mammography. (2020) (17)
Quantitative Fit Tested N95 Respirator-Alternatives Generated With CT Imaging and 3D Printing: A Response to Potential Shortages During the COVID-19 Pandemic (2020) (17)
Kinetics of interstitially administered monoclonal antibodies for purposes of lymphoscintigraphy. (1987) (17)
Preliminary results from intensity‐based CT‐SPECT fusion in I‐131 anti‐B1 monoclonal‐antibody therapy of lymphoma (1997) (17)
Unsatisfactory hepatic perfusion after placement of an implanted pump and catheter system: angiographic correlation. (1989) (16)
Radiosynthesis of [11C]paclitaxel (2002) (16)
Metastatic angiosarcoma with thrombocytopenia and intratumoral indium-111-platelet deposition. (1991) (16)
Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines (2009) (16)
Simultaneous pancreatic-renal transplant scintigraphy. (1986) (16)
MECHANISMS IN ENDOCRINOLOGY: Impact of isolated TSH levels in and out of normal range on different tissues. (2015) (16)
Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. (2015) (16)
Respiratory‐gated PET/CT versus delayed images for the quantitative evaluation of lower pulmonary and hepatic lesions (2014) (16)
Synthesis and Biodistribution of [11C]Adenosine 5′-Monophosphate ([11C]AMP) (2005) (16)
Studies on the metabolic fate of 111In-labeled antibodies. (1989) (16)
A Snapshot of Radiology Training During the Early COVID-19 Pandemic (2020) (16)
In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. (2006) (16)
Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. (2014) (16)
99Tcm-MDP uptake by lymph nodes following tracer infiltration: clinical and laboratory evaluation (1987) (16)
Diagnosis of unilateral mainstem bronchial obstruction following single-lung transplantation with routine spirometry. (1993) (15)
Synthesis and in vivo evaluation of (S)-6-(4-fluorophenoxy)-3-((1-[11C]methylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one, a potential PET tracer for growth hormone secretagogue receptor (GHSR). (2011) (15)
Hyperthyroidism with or without pyramidal lobe Graves' disease or disseminated autonomously functioning thyroid tissue? (1997) (15)
Stereotactic coordinates from ECT sinograms for radionuclide-guided breast biopsy. (1996) (15)
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. (2021) (15)
Monoclonal Antibody Radioimmunodetection of Human-derived Colon Cancer (1982) (15)
Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? (2016) (15)
Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability (2017) (15)
Repeatability of brown adipose tissue measurements on FDG PET/CT following a simple cooling procedure for BAT activation (2019) (14)
Biotinylated iodo-polylysine for pretargeted radiation delivery. (1993) (14)
The utility of SPECT for 99mTc-MAA hepatic arterial perfusion scintigraphy. (1985) (14)
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. (2016) (14)
Impact of Obesity and Bariatric Surgery on Metabolism and Coronary Circulatory Function (2013) (14)
Experimental radioimmunotherapy. A brief overview (1994) (14)
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines) (2022) (14)
I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images. (1999) (14)
Imaging Uterine Cervical Cancer with FDG-PET/CT: Direct Comparison with PET (2009) (14)
The pharmacokinetics of the kininogens. (1998) (13)
Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre (2022) (13)
Factors affecting the repeatability of gamma camera calibration for quantitative imaging applications using a sealed source (2015) (13)
Synthesis and biological evaluation of radioiodinated phospholipid ether stereoisomers. (1995) (13)
Oxalic Acid in Saliva, Teeth and Tooth Tartar (1994) (13)
Monoclonal antibody radioimmunodetection of human-derived colon cancer. (1983) (13)
SPECT of the peritoneal cavity: method for delineating intraperitoneal fluid distribution. (1989) (13)
Lymphoscintigraphy in melanoma: initial evaluation of a low protein dose monoclonal antibody cocktail. (1990) (13)
Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer. (2002) (13)
Lymphatic anatomy: functional nodal basins. (1988) (13)
Improved radiolabeled monoclonal antibody uptake by lavage of intraperitoneal carcinomatosis in mice. (1989) (13)
Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. (1998) (12)
Clinical significance of discordant findings between pre-therapy (123)I and post-therapy (131)I whole body scan in patients with thyroid cancer. (2013) (12)
Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer (2018) (12)
Two-time-point FDG PET/CT: liver SULmean repeatability. (2015) (12)
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma (2017) (12)
I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years (2007) (12)
EQPlanar: a maximum-likelihood method for accurate organ activity estimation from whole body planar projections (2011) (12)
Brown Adipose Tissue Response Dynamics: In Vivo Insights with the Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium (2015) (12)
Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. (2007) (12)
Antitumor effects of arsenic trioxide in transformed human thyroid cells. (2008) (12)
Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer (2008) (11)
Radioimmunoimaging of human small cell lung carcinoma xenografts in nude mice receiving several monoclonal antibodies. (1987) (11)
Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma. (2000) (11)
Arterial Wall Dosimetry for Non-Hodgkin Lymphoma Patients Treated with Radioimmunotherapy (2010) (11)
FDG positron emission tomography detection of pelvic nodal metastases in gynecologic cancer. (2002) (11)
Site-specific radiolabeling of monoclonal antibodies with biotin/streptavidin. (1989) (11)
Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). (2006) (11)
Novel parametric PET image quantification using texture and shape analysis (2012) (11)
Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts (2015) (11)
Simplifying volumes‐of‐interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole‐organ VOIs (2017) (11)
Quantitative FDG PET/CT in the community: Experience from interpretation of outside oncologic PET/CT exams in referred cancer patients (2014) (11)
The QIBA profile for quantitative FDG-PET/CT oncology imaging (2014) (10)
Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms (2017) (10)
Direct effects of protirelin (TRH) on cultured porcine thyrocytes (1992) (10)
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. (2021) (10)
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer (2021) (10)
Characterization of a Perirectal Artifact in 18F-FDG PET/CT (2010) (10)
Anatomolecular imaging with 2-deoxy-2-[18F]fluoro-D-glucose: bench to outpatient center. (2003) (10)
Magnetically enhanced radionuclide therapy. (1994) (10)
Dynamic variable background subtraction: a simple means of displaying radiolabeled monoclonal antibody scintigrams. (1986) (10)
At Last, 18F-FDG for Inflammation and Infection! (2021) (10)
Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy (2020) (10)
Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts. (1993) (10)
Remodelling of the Myocyte at a Molecular Level — Relationship Between Myosin Isoenzyme Population and Sarcoplasmic Reticulum (1987) (9)
Beta-sensitive intraoperative probes utilizing dual, stacked ion-implanted-silicon detectors: proof of principle (1998) (9)
Repeatability of 18F-FDG PET Radiomic Features in Cervical Cancer (2020) (9)
Patient motion artifacts on scintigraphic gastric emptying studies. (1985) (9)
Intraperitoneal delivery of monoclonal antibodies: enhanced regional delivery advantage using intravenous unlabeled anti-mouse antibody. (1987) (9)
Comprehensive modeling of the spatiotemporal distribution of PET tracer uptake in solid tumors based on the convection-diffusion-reaction equation (2014) (9)
Repeatability of Radiotracer Uptake in Normal Abdominal Organs with 111In-Pentetreotide Quantitative SPECT/CT (2015) (9)
Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical 18F-FDG PET Imaging of Triple-Negative Breast Cancer Patient–Derived Tumor Xenografts (2019) (9)
Improved monoclonal antibody tumor/background ratios with exchange transfusions. (1991) (9)
Generalized population-based input function estimation given incomplete blood sampling in quantitative dynamic FDG PET studies (2012) (9)
Effects of retinol on follicular porcine thyrocytes in culture (1999) (9)
Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: a potential approach to brain tumor immunotherapy. (1990) (9)
Products of cells cultured from gliomas. V. Cytology and morphometry of two cell types cultured from glioma. (1987) (9)
High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts (2004) (9)
Magnetically-enhanced radionuclide therapy (MERiT): in vitro evaluation. (1997) (9)
18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters (2014) (9)
Effects of Retinoids on Porcine Thyrocytes under Different Culture Conditions (2001) (9)
Biological disposition and imaging of a radioiodinated alkylphosphocholine in two rodent models of breast cancer. (1996) (8)
Decontamination puts meat in a pickle (1986) (8)
Site-specific radiolabelling of monoclonal antibodies with blotin/streptavidin (1989) (8)
Positron Emission Tomography (PET): an update on applications in breast cancer. (1998) (8)
Overcorrection of iodinated contrast attenuation in SPECT-CT: phantom studies. (2010) (8)
Overview of the current status of PET in breast cancer imaging. (1998) (8)
Autoradiography-based, three-dimensional calculation of dose rate for murine, human-tumor xenografts. (1993) (8)
PET/CT findings in gastric cancer: Potential advantages and current limitations (2012) (8)
Adsorption equilibria of thyroid hormones in the liver cell. (1977) (8)
Spectral analysis using regularized non-negative least-squares estimation [positron emission tomography] (1995) (8)
Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. (2015) (8)
Optimal definition of biological tumor volume using positron emission tomography in an animal model (2015) (8)
Lymphatic Anatomy: Functional Nodal Basins (1989) (8)
Intraperitoneal (IP) delivery of radiolabeled monoclonal antibody to IP-induced xenografts of human ovarian cancers (1985) (7)
Human Radiation Dosimetry for Orally and Intravenously Administered 18F-FDG (2020) (7)
Radioimmunoscintigraphic detection of occult gestational choriocarcinoma. (1987) (7)
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels (2021) (7)
Selective localization of radioiodinated alkylphosphocholine derivatives in tumors. (1992) (7)
Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin’s Lymphoma: Feasibility and Initial Safety (2008) (7)
Radiolabeled antibodies, albumin and antimony sulfide colloid: a comparison as lymphoscintigraphic agents. (1988) (7)
A semi-automated fluorescent (SAF) assay using viable, whole cells for screening hybridoma supernatants. (1987) (7)
Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. (1985) (7)
Cardiosphere-Derived Cells Demonstrate Metabolic Flexibility That Is Influenced by Adhesion Status (2017) (7)
Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. (2010) (7)
DNA Repair After Exposure to Ionizing Radiation Is Not Error-Free (2017) (7)
The effect of specimen processing on radiolabeled monoclonal antibody biodistribution (2004) (7)
Reproducibility of liver and mediastinal blood pool F-18 activity as normal reference tissues (2011) (7)
Physiological Role and Use of Thyroid Hormone Metabolites - Potential Utility in COVID-19 Patients (2021) (7)
[Iodine content in diet and excretion of iodine in urine]. (1995) (6)
Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: theory of application. (1995) (6)
Towards parametric whole-body FDG PET/CT imaging: Potentials for enhanced tumor detectability (2012) (6)
Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. (2005) (6)
Gastric air contrast: useful adjunct to hepatic artery scintigraphy. (1984) (6)
Quantitative evaluation of 2-deoxy-2-[18F] fluoro-D-glucose uptake in hepatic metastases with combined PET-CT: iterative reconstruction with CT attenuation correction versus filtered back projection with 68Germanium attenuation correction. (2002) (6)
The use of a vasoconstrictor to improve tumour blood flow in intra‐arterial chemotherapy: preliminary report (1985) (6)
Synthesis of 2‐[18F]fluoroadenosine (2‐[18F]FAD) as potential radiotracer for studying malignancies by PET (2006) (6)
Disulfide bond-targeted radiolabeling: tumor specificity of a streptavidin-biotinylated monoclonal antibody complex. (1990) (6)
The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL). (2006) (6)
Synthesis and biological evaluation of radioiodinated phospholipid ether analogs. (1995) (6)
Systemic perfusion: a method of enhancing relative tumor uptake of radiolabeled monoclonal antibodies. (1988) (6)
Hepatic imaging. (1989) (6)
Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma (NHL) (2005) (6)
Theranostics: The Role of Quantitative Nuclear Medicine Imaging. (2021) (6)
Iodine-125-MIBG Therapy for Neuroblastoma—Reply (1991) (6)
Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma (2016) (6)
Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/paraganglioma (Pheo). (2012) (5)
Streptavidin-biotinylated IgG conjugates: a simple procedure for reducing polymer formation. (1992) (5)
Dynamic FDG PET imaging using direct 4D parametric reconstruction in cancer patients (2010) (5)
2013 SNMMI Highlights Lecture: oncology. (2013) (5)
Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas (2010) (5)
Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types? (2012) (5)
Retinol has specific effects on binding of thyrotrophin to cultured porcine thyrocytes. (2004) (5)
Overview of the First NRG Oncology–National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy (2020) (5)
Quality control in mammography: an initiative in France. (1994) (5)
Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer (2021) (5)
Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies (2012) (5)
The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma (2013) (5)
A positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients. (2003) (5)
Passive transport of thyroid hormones from extravascular space into the circulation. (1990) (5)
Adenocarcinoma of the alimentary tract: peritoneal distribution scintigraphy. (1987) (5)
Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™ (2021) (5)
Nanoparticles: Promising Auxiliary Agents for Diagnosis and Therapy of Thyroid Cancers (2021) (5)
Decrease in dipeptidyl peptidase IV activity is linked to the efficacy of differentiating compounds in follicular thyroid carcinoma cell lines. (2011) (5)
Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge (2020) (5)
Quality Control in Mammography: The Pilot Campaign of Breast Screening in the Bas-Rhin Region (1995) (5)
[Thyrotoxic crisis: symptoms and therapy (author's transl)]. (1973) (5)
Is enteral administration of fluorine-18-fluorodeoxyglucose (F-18 FDG) a palatable alternative to IV injection? Pre-clinical evaluation in normal rodents. (2002) (5)
Biodistribution and therapeutic effects of radiolabeled metaiodobenzylguanidine in a human neuroblastoma xenograft (1992) (5)
Cellular Bioenergetics Is an Important Determinant of the Molecular Imaging Signal Derived From Luciferase and the Sodium-Iodide Symporter (2013) (5)
An overview of clinical PET/CT (2006) (5)
Quo Vadis: PET and Single-Photon Molecular Breast Imaging (2016) (4)
Machine Learning-Based Noninvasive Quantification of Single-Imaging Session Dual-Tracer 18F-FDG and 68Ga-DOTATATE Dynamic PET-CT in Oncology (2021) (4)
The importance of brown adipose tissue. (2009) (4)
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy. (2004) (4)
Metrology standards for Quantitative imaging Biomarkers 1 (2015) (4)
Oxalate in human seminal plasma: possible significance and problems of oxalate determination. (2000) (4)
Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML) (2014) (4)
Enhanced whole-body PET parametric imaging using hybrid regression and thresholding driven by kinetic correlations (2012) (4)
Dynamic Graded Subtraction: A Simple Method to Background Correct and Display Multicompartmental Radiopharmaceutical Scintigrams (1985) (4)
Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat (2005) (4)
NUKDOS: A software tool for dosimetry prior to molecular radiotherapy (2014) (4)
Monoclonal antibody radioimmunodetection of transplant rejection. (1985) (4)
A novel imaging method for assessing vessel wall inflammation: Dynamic multi-bed PET parametric imaging (2013) (4)
Clinical experience with Tc-99m labeled (N2S2) anti-melanoma antibody fragments and single photon emission computed tomography. (1992) (4)
Radiolabeled monoclonal antibodies for the diagnosis and treatment of ovarian carcinoma. (1990) (4)
Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008). (2012) (4)
Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient (2005) (4)
A Projection-Domain Low-Count Quantitative SPECT Method for ɑ-Particle-Emitting Radiopharmaceutical Therapy (2021) (4)
Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy (2021) (4)
An Exocrine Pancreatic Stress Test with 11C-Acetate PET and Secretin Stimulation (2014) (4)
Society of Nuclear Medicine Procedure Guideline for Tumor Imaging Using F-18 FDG version 2 . 0 , approved February 7 , 1999 (1999) (4)
Comparison of lung shunt fraction (LSF) from pre-therapy 99mTc MAA and post-therapy quantitative 90Y imaging in microsphere (MS) radioembolization (2015) (4)
Biodistribution, metabolism, and excretion of radioiodinated phospholipid ether analogs in tumor-bearing rats. (1993) (4)
Suspected obstructive pyelocaliectasis: Doppler ultrasonography compared with diuretic renal scintigraphy in proven cases. (1996) (3)
Contrast Enhanced Computed Tomography Characterization of Fluorodeoxygluocose-Avid Regional and Non-Regional Lymph Nodes in Patients with Suspicion of Metastatic Bladder Cancer (2013) (3)
Longitudinal Myocardial Blood Flow Gradient and CAD Detection (2014) (3)
Importance of the terminal portion of tumor time-activity curve in determining tumor dosimetry in radioimmunotherapy. (1991) (3)
Characterization of sucrose-induced changes in cardiac phenotype (2002) (3)
Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center (2022) (3)
34.15 Effects of misregistration between SPECT and CT for attenuation corrected myocardial perfusion single photon emission tomography (2005) (3)
Influence of unlabeled monoclonal anti-mouse antibody on the clearance rate of radiolabeled mouse monoclonal antibody (1985) (3)
TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer. (2018) (3)
FDG-PET/CT in assessing ovarian cancer recurrence and patient outcome: Comparison to CA-125 (2009) (3)
Diagnosis of exercise-induced left bundle branch block at rest by scintigraphic phase analysis (1986) (3)
The “water-ida”: A simple means to separate duodenal from gallbladder activity on cholescintigraphic studies (1984) (3)
Isotype switch variant anti-idiotype monoclonal antibodies: comparative radiolabeling and in vitro binding. (1989) (3)
Single photon emission computed tomography in cancer imaging. (1993) (3)
Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks (2018) (3)
SPECT Imaging of Myocarditis (1987) (3)
Basal lamina formation by porcine thyroid cells grown in collagen- and laminin-deficient medium (2004) (3)
Effects of human thyroxine-binding globulin and prealbumin on the reverse flow of thyroid hormones from extravascular space into the bloodstream in rabbits. (1989) (3)
A simplified method for determining therapeutic activity to administer for radioimmunotherapy (1996) (3)
124-I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: Real-time treatment planning (2009) (3)
Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice. (2021) (3)
Detection of gastritis by 99mTc-labeled red-blood-cell scintigraphy. (1984) (3)
Successful gallium-67 imaging of North American pulmonary blastomycosis. (1993) (3)
Left ventricular potentiation at a reduced exercise level: a cause of false-negative radionuclide ventriculograms. (1986) (3)
Applications of Pet in Oncology (2005) (3)
Oxalate in the Human Thyroid Gland (1993) (3)
Impact of isolated TSH levels in and out of normal range on different tissues (2015) (3)
Progress in nuclear medicine imaging of cancers. (1998) (2)
Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. (2014) (2)
Diagnostic Accuracy of 99mTc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses (2022) (2)
Implementation and evaluation of a dynamic whole-body PET/CT protocol (2012) (2)
Efficiency of various dissociation methods for the preparation of thyroid single cell suspensions. (2009) (2)
Re-treatment with Tositumomab and Iodine I 131 Tositumomab in patients with non-Hodgkin lymphoma who had previously responded to Tositumomab and Iodine I 131 Tositumomab (2005) (2)
Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century. (2021) (2)
Bioluminescent Tumor Signal Is Mouse Strain and Pelt Color Dependent: Experience in a Disseminated Lymphoma Model (2021) (2)
Choline uptake and RNA expression profile in cancerous and normal prostate cell lines: No significant role of choline transporter in PET tracer uptake (2007) (2)
Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts (2005) (2)
Reproducibility of SUV max for oncologic PET: Significant differences in quantification of the SAME study between PET-only and PET-CT analysis modes (2008) (2)
Current Landscape of Radiopharmaceutical Therapies: SNMMI Therapy Task Force Survey. (2021) (2)
Diabetic oesophagoparesis: assessment by solid phase radionuclide scintigraphy (1986) (2)
Nonmyeloablative Iodine-13 1 Anti-B 1 Radioimmunotherapyas Outpatient Therapy (1998) (2)
Abstract 1767: Feasibility of In Vivo Cardiac Stem Cell Tracking, by SPECT and PET Imaging, Using the Sodium-iodide Symporter as Reporter Gene (2007) (2)
Spect with 2[fluorine-18]fluoro-2-Deoxy-D-Glucose (fdg) - Reply (1995) (2)
Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies (1997) (2)
Quantitation of Cancer Treatment Response by FDG PET/CT: Multi-center Assessment of Measurement Variability Using AUTO-PERCISTTM (2020) (2)
Molecular Imaging in Oncology (2003) (2)
Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks (2019) (2)
Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade (2021) (2)
The impact of PET pixel size on contrast recovery for small lesions (2009) (2)
How often are statistically significant results clinically relevant? Not often (2009) (2)
Receiver operating characteristic (ROC) analysis of amino acid transporters in 136 prostate cancer samples (2015) (2)
Basal lamina formation by porcine thyroid cells grown in collagen- and laminin-deficient medium (1995) (2)
Three-Dimensional Radiobiological Dosimetry ( 3 DRD ) : Application of Radiobiological Modeling to Patient-Specific , 3-D Imaging-based Internal Dosimetry (2007) (2)
Radionuclide Therapy of Lymphomas (2016) (2)
Abstract 16604: Discrepant Uptake of the Sympathetic Nerve Imaging Tracers Hydroxyephedrine (HED) and Metaiodobenzylguanidine (MIBG) in Rat Hearts (2011) (2)
Diagnosis of Stage IV Melanoma (2020) (2)
Need for Objective Task-based Evaluation of Deep Learning-Based Denoising Methods: A Study in the Context of Myocardial Perfusion SPECT (2023) (2)
Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma (2022) (2)
Immunolymphoscintigraphy in breast cancer: evaluation using 131I-labeled monoclonal antibody B72.3. (1998) (2)
Nuclear medicine techniques in breast imaging. (1996) (2)
Increased genital uptake of 99mTc red blood cells: A potential cause of false-positive studies for gastrointestinal bleeding (2004) (2)
Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials (2023) (2)
Combined PET/CT/MRI of the pelvis using software registration (2013) (2)
Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network (2020) (2)
Initial evaluation of respiratory gated PET/CT of upper abdominal lesions (2008) (2)
The Roles of Fluorodeoxyglucose-PET/Computed Tomography in Ovarian Cancer: Diagnosis, Assessing Response, and Detecting Recurrence. (2010) (2)
Chronic cardiac reactions. IV. Effect of drugs and altered functional loads on cardiac energetics as inferred from myofibrillar ATPase and the myosin isoenzyme population. (1987) (2)
Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab (2015) (2)
Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy. (2007) (2)
Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using 213Bi-Anti-CD20 Monoclonal Antibody (2022) (2)
A multi-site study of a breast density deep learning model for full-field digital mammography and digital breast tomosynthesis exams (2020) (2)
High response rate to Bexxar in advanced stage prior treatment-resistant follicular lymphoma (2005) (1)
Assessing PERCIST 1.0 non-measurable (low FDG uptake) lesions in patients with breast cancer does not diminish the predictive value of FDG PET (2013) (1)
2532 : Does the Pattern of Failure Impact the Use of Single-Agent 131I-Tositumomab for Follicular Lymphoma? (2006) (1)
New Diagnostic and Therapeutic Tools for Thyroid Cancer (2013) (1)
[Selective blocking of thyroid adenomas using small doses of perchlorate]. (1978) (1)
The success and failure of radioimmunotherapy for lymphoma (2016) (1)
Quantitative potential of Y-90 PET (2011) (1)
Tomographic renal cortical scintigraphy: Correlation with intravenous urography, computed tomography, ultrasonography, angiography, and nuclear magnetic resonance imaging (2004) (1)
Pancreatic Tumor Delineation with FDG-PET/CT: Smaller Volumes and Regions not Identified with CT Alone (2008) (1)
Molecular basis of brown adipose tissue accumulation of FDG and MIBI (2010) (1)
The (F)utility of the thallium-201 quantitative lung/myocardial ratio in the detection of coronary artery disease (2004) (1)
Sublingual Thyroid Gland (2014) (1)
Star Trek Meets the Operating Room: Nurse Scotty, Beam Me Up—A Tricorder (2016) (1)
Repeatability of Radiomic Features of Brown Adipose Tissue (2020) (1)
How many lesions to measure for response assessment? Comparing SULpeak changes in a single lesion and the sum of the 5 hottest lesions in 3 types of cancer and 3 types of therapy (2013) (1)
Human biodistribution and radiation dosimetry of 18F-fluorobenzyltriphenyl phosphonium (2012) (1)
SUL-PEAK, -MAX and -PAX in PERCIST 1.0: An ROC analysis (2012) (1)
Erratum: Targeting of VX2 rabbit liver tumor by selective delivery of 3-Bromopyruvate: A biodistribution and survival study (Journal of Pharmacology and Experimental Therapeutics (2008) 327 (32-37)) (2015) (1)
Feasibility of parametric imaging in multi-bed dynamic human FDG PET (2010) (1)
Identification of a characteristic perirectal artifact in FDG PET/CT (2010) (1)
Evaluation of 18F-FDG-PET/CT for Response Assessment in Patients with Advanced Melanoma Treated with Pembrolizumab Checkpoint Inhibitor Monotherapy (2018) (1)
[Thyrotoxic crisis: symptomatology and therapy. 2]. (1973) (1)
Myosin isoenzyme population and rate of Ca-uptake of sarcoplasmic reticulum of rat ventricles in diabetes, intermittent fasting or pressure load — The differential influence of circulating thyroid hormones (1987) (1)
Kinetics of intralymphatically delivered monoclonal antibodies (1985) (1)
PET and PET/CT Imaging in Breast Cancer (2006) (1)
QIN. Promise and pitfalls of quantitative imaging in oncology clinical trials (2012) (1)
PET/CT evaluation of bronchioloalveolar carcinoma: Correlation with CT and FDG/PET findings (2007) (1)
13N-ammonia: A novel biomarker for blood flow-dependent imaging of brown adipose tissue in rodents and humans (2016) (1)
Determination of absolute flow quantification: Comparison of different software packages and methods (2012) (1)
Painful Schmorl's node: another cause of vertebral photopenia on Indium-111-labeled leukocyte scintigraphy. (1999) (1)
SU‐GG‐I‐145: Quantifying the Increase in Radiation Exposure Associated with SPECT/CT Compared to SPECT Alone for Routine Nuclear Medicine Examinations (2008) (1)
Brain 18F-FDG PET/CT findings in patients with possible paraneoplastic syndrome (2011) (1)
Study of iterative SPECT corrective reconstruction methods for lesion detection and localization in In-111 ProstaScint(R) imaging by means of combination of Monte-Carlo simulations and clinical evaluation techniques (2006) (1)
Inter-observer variability of quantitative FDG PET and CT measurements of tumor response to therapy (2007) (1)
12 Differentiation Therapy in Thyroid Carcinoma (2018) (1)
Factors affecting hematotoxicity after 90Y-ibritumomab tiuxetan or 131I-tositumomab radioimmunotherapy (2008) (1)
Studies on the Metabolic Fate of I1 'In-labeled Antibodies (1989) (1)
Direct effect of protirelin (TRH) on PB[123I] in autonomous thyroid adenoma. (1993) (1)
The who and what of imaging in sarcoma and correlation with survival. (2015) (1)
Time dependence of hypoxia-specific accumulation of pimonidazole in rodent breast cancers (2010) (1)
Dynamic whole-body 68Ga-DOTATOC PET/CT (2015) (1)
Positron emission tomography in cancer patient management. (1999) (1)
A deep learning algorithm for reducing false positives in screening mammography (2022) (1)
Mathematical modelling of intravascular thyroid hormone stimulation by carrier proteins. (1982) (1)
Title : Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90 Y-ibritumomab tiuxetan or 131 I-tositumomab (1)
Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin (2019) (1)
assessment Quantitative imaging biomarkers: A review of statistical methods for technical performance (2014) (1)
Incidence and correlates of increased coronary calcium in patients with normal myocardial perfusion utilizing an integrated hybrid SPECT-CT (2007) (1)
Products of cells from gliomas: VIII. Multiple-well immunoperoxidase assay of immunoreactivity of primary hybridoma supernatants with human glioma and brain tissue and cultured glioma cells. (1990) (1)
Comparison of a four-day recombinant thyrotropin regimen with thyroid hormone withdrawal to prepare for postoperative radioiodine ablation of thyroid remnants in patients with thyroid carcinoma (2010) (1)
Comprar Principles and Practice of PET/CT 2/e | Richard L. Wahl | 9780781779999 | Lippincott Williams & Wilkins (2008) (1)
Model-based downscatter estimation in simultaneous I-131/In-111 dual-isotope SPECT imaging (2006) (1)
Novel applications, oral abstract session V10.3: Radiolabelling of cardiac-derived stem cells with FDG for PET imaging of therapeutic cell delivery (2007) (1)
Indium-111 leukocyte uptake in a patient with osseous metastatic Ewing's sarcoma. (1993) (1)
Diagnostic performance of F18-FDG PET/CT in patients with suspected paraneoplastic syndrome (2014) (1)
Metabolic activity measured by 18F-FDG PET/CT in newly diagnosed patients with lymphoma: Correlation with immunophenotype (2013) (1)
Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors (2022) (1)
Understanding the Role of 18Flurodeoxyglucose PET in Predicting Improved Survival in Locally Advanced Pancreatic Cancer. (2013) (1)
Correlation of K-ras mutation with FDG uptake in colorectal cancer (2010) (1)
Intraperitoneal delivery of monoclonal antibodies. (1990) (1)
SYNTHESIS AND EVALUATION OF A RADIOIODINATED PHOSPHOLIPID ETHER ANALOG (NM-404) FOR DIAGNOSTIC IMAGING OF PROSTATE CANCER (2000) (1)
Abstract 4533: Synthesis and biodistribution of225Ac-substance P for intracavitary radiopharmaceutical therapy of high-grade recurrent glioma. (2013) (1)
Auto-PERCIST: Semi-automated response assessment of FDG-PET based on PERCIST 1.0 and other criteria. (2015) (1)
Positron Emission Tomography and Cancer (2006) (1)
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting. (2022) (1)
Differentiation Therapy in Thyroid Carcinoma (2012) (1)
Dual-photon bone mineral density in the proximal femur: correlation by site. (1988) (1)
FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: Characteristics of HPV-positive and HPV-negative tumors (2013) (1)
Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane (nca-MIBG) in patients with malignant pheochromocytoma (Pheo). (2011) (1)
A PERCIST 1.0 based Computer Assisted Detection (CAD) system: Performance compared to an expert reader in the evaluation of breast cancer (2011) (1)
Principles and Practice of PET/CT 2/e (2008) (1)
[Thromboplastin activity of extracts of human thyroid glands (author's transl)]. (1978) (1)
The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors. (2020) (1)
Passive microwave radiometry for the non-invasive detection of human brown fat: First human studies with direct correlation to FDG/PET (2014) (1)
Early treatment response by FDG PET in patients with the Ewing sarcoma family of tumors predicts survival (2013) (1)
Abundance of thymidine kinase 1 (TK1) message in breast cancer cell lines is better correlated with their doubling times than Ki67 or PCNA message levels (2014) (1)
Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing 99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year Experience (2022) (1)
Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies. (2022) (1)
Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem (2022) (1)
SNMMI Leadership Update: SNMMI's Role in the Nuclear Medicine Renaissance. (2022) (1)
ACR Stakeholder Prostate Summit. (2020) (1)
SNMMI Leadership Update: Call the Nuclear Oncologist. (2022) (1)
Aortic wall modeling/dosimetry in lymphoma patients treated with radioimmunotherapy (2009) (0)
Assessment of non-specific binding and optimization of the uptake time for 18F-FMISO hypoxia detection: Correlation with pimonidazole (2011) (0)
High resolution 18F-FDG small joint positron emission mammography arthroPET imaging (2012) (0)
Comparison of two methods for measuring liquid gastric emptying (2014) (0)
Effects of IV contrast on quantitative PET/CT parameters (2006) (0)
DETECTION OF CUTANEOUS B- CELL LYMPHOMA WITH In-111 PENTETREOTIDE: A FIRST REPORT (1995) (0)
Rapamycin induced "stunning" on FDG PET/CT in pancreatic cancer (2008) (0)
A survey of normal reference hepatic SUL variability in whole body PET (2012) (0)
Invited oral presentations (1997) (0)
Impact of initial FDG PET/CT on stage and radiation therapy in newly-diagnosed pediatric Hodgkin's lymphoma (2008) (0)
Abstract 15881: Delayed Enhancement in Hypertrophic Cardiomyopathy Is Related to Perfusion Abnormalities: An Ischemia-Fibrosis Connection (2011) (0)
Cellular metabolism is an important determinant of 99mTc uptake by the sodium-iodide symporter (2012) (0)
Multicenter quantitative assessment of treatment response by FDG PET/CT (2014) (0)
Importance of the same or different readers pre- and post-therapy for anatomic vs. metabolic response assessments (2011) (0)
A Comparison of Semi-Automated Brown Adipose Tissue Segmentation Methods (2020) (0)
Need for objective task-based evaluation of deep learning-based denoising methods: A study in the context of myocardial perfusion SPECT. (2023) (0)
Colorectal and hepatobiliary tumors (2005) (0)
Quantifying metabolic tumor response to therapy: Total lesion glycolysis and partial volume reduction. (2009) (0)
Contrast recovery in positron emission mammography (2011) (0)
Time-dependent analysis of 18F-FLT distribution in rat mammary tumors (2011) (0)
ROC-analysis of quantitative NaF PET SUL in detecting malignant vs. benign skeletal lesions (2012) (0)
Minimizing variation in uptake times in a busy multi- camera PET/CT oncology clinic (2009) (0)
Imaging of tumors using PET (1994) (0)
Transcriptome foundations of low FDG uptake in prostate cancer (2009) (0)
14 Quantitative Assessments of Tumor Response with FDG PET, PERCIST and Beyond (2012) (0)
Lymphoma response criteria should include a metabolic assessment of bone marrow disease (2008) (0)
Comparative gene expression related to the uptake of PET radiotracers in prostate cancer cell lines (2012) (0)
A regression model to predict tumor cellularity in patients with prostate cancer and low FDG uptake (2015) (0)
Title: Repeatability of Radiomic Features of Brown Adipose Tissue Running Title: BAT Radiomic Repeatability (2020) (0)
Optimizing injected activity in whole-body 3D PET: Relating NECR and singles rates (2007) (0)
Reply to E. Hindié et al. (2019) (0)
Rapid quantitative assessment of phagocytic activity of Indium-111 labeled leukocytes by chemiluminescence (1985) (0)
Preclinical and Clinical Evaluation of Novel Agents for Noninvasive Imaging of Prostate Cancer (2002) (0)
829 Effect of hypoxic cell sensitization on glucose metabolism of squamous-cell carcinoma (1995) (0)
Change in tumor-to-liver uptake ratios is comparable to PERCIST 1.0 in predicting complete response in primary breast cancer systemic therapy (2013) (0)
Inter-reader variability of PET parameters in pancreatic adenocarcinoma: Impact of early and delayed images (2013) (0)
Inter-reader reliability and variability of 18F-FDG PET volumetric tumor parameters in sarcoma (2013) (0)
PET/CT imaging in pancreatic cancer: A retrospective review (2009) (0)
Diagnostic applications of nuclear medicine: Lymphomas (2017) (0)
Neurology and psychiatry (2005) (0)
Evaluation of image derived input function methods for quantification of dynamic whole-body FDG PET-CT (2013) (0)
Examining the effect of patient body size on 2D and 3D PET (2008) (0)
Gamma camera count rate performance assessment without specialized equipment (2012) (0)
Quantitative Imaging Biomarker Alliance (QIBA): Overview and Emphasis on Nuclear Medicine Based Approaches (2017) (0)
Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow (2022) (0)
Individualizing cancer therapies using "anatomolecular" imaging. (2008) (0)
Clinical PET/CT in the community: Experience from interpretation of outside PET/CT exams in referred patients: Methods and quantitation (2010) (0)
Progress in Prostate Cancer Theranostics. (2021) (0)
Factors affecting repeatability of activity quantification in SPECT/CT (2013) (0)
Cost efficacy of PET/CT versus CT in relapsed diffuse large B-cell lymphoma (2008) (0)
Effect of retinoids, histondeacetylase inhibitors and glitazones on the differentiation of cultured transformed thyrocytes (2005) (0)
Individualizing cancer therapies using "anatomolecular" imaging. (2008) (0)
Infection and inflammation (2005) (0)
Contrast media and radiopharmaceutical agents: regulatory issues. (1995) (0)
Time course of tissue uptake of L-methionine as a potential pancreatic imaging agent: Rodent studies (2009) (0)
Imaging Metabolic and Molecular Functions in Brain Tumors with Positron Emission Tomography (PET) (2014) (0)
Quantitative assessment of tumor response in patients with lymphoma and bone marrow involvement by PET/CT (2008) (0)
Potentiation of left ventricular function at a reduced exercise level: Assessment by radionuclide ventriculography (1984) (0)
Gastric xenon trapping mimicking COPD: Recognition using an effervescent agent (2004) (0)
Determination of metabolic tumor response by FDG PET is highly reproducible with the same or different readers pre- and post-therapy (2009) (0)
Henry N. Wagner, Jr, MD (2014) (0)
In vivo localization and quantification of mitochondrial dysfunction using PET imaging of the novel voltage sensor 18F-FBnTP (2012) (0)
The inverse relationship of oxidative phosphorylation (OXPHOS) and glycolysis in rat mammary tumor (RMT) revealed by the PET biomarkers fluorobenzyl triphenyl phosphonium (FBnTP) and FDG (2010) (0)
Assessing radio immunotherapy of disseminated lymphomas with non-invasive in vivo bioluminescence (2007) (0)
Trends of quality control practices in multicenter PET/CT facilities (2013) (0)
Unraveling brown adipose tissue (BAT) thermogenic makeup using 18F-fluorobenzyl triphenyl phosphonium (FBnTP) and FDG PET in humans (2013) (0)
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer (2021) (0)
Effect of nicotine and ephedrine on brown adipose fat tissue accumulation of FDG with rodent studies (2006) (0)
Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck (2012) (0)
3H-Adenosine 5'-monophosphate (3H-AMP) lung uptake as a marker of normal pulmonary function in a mouse model of LPS induced lung inflammation (2007) (0)
Performance comparison of Auto-PERCIST (a semi-automated PERCIST-based CAD system) and a clinician in the measurement of PERCIST 1.0 metrics for response assessment (2014) (0)
In vitro evaluation of Rituxan as a radiosensitization agent for non-Hodgkin's lymphoma (2007) (0)
Evaluation of asymmetry index of temporal lobes on 18FDG PET/CT localizing the epileptogenic zone in drug resistant temporal lobe epilepsies (2011) (0)
Low-dose propranolol is safe for use in pediatric patients to decrease FDG brown adipose tissue uptake (2013) (0)
Magnetically-enhanced reduction of radiation dose to bone marrow from bone-avid radiopharmaceuticals (1995) (0)
131I Therapy in Non-Hodgkin’s Lymphoma (2004) (0)
Use of combined PET/CT imaging in evaluation of the solitary pulmonary nodule: Principles, techniques, and pitfalls (2006) (0)
Surveillance of Cancer Patients with Imaging: Self-Evident or Evidence-Based? (2013) (0)
[Effect of diiodophenolsulfonic acid (DIPS) on the iodine metabolism of rats and on the binding of thyroxine to human serum prealbumin]. (1973) (0)
Diagnostic concordance of I-123 whole body scan for the evaluation of residual thyroid tissue and metastatic thyroid cancer compared to post-ablation I-131 scan (2010) (0)
Enhancing anti-CD20 directed radioimmunotherapy. Preliminary studies using lenalidomide-accelerated internalization (2009) (0)
213Bi-Anti-CD20 RIT and bioluminescent imaging of micrometastatic B-cell lymphoma (2010) (0)
Comprehensive esophago-gastro-intestinal transit study: Methodology and normal values (2014) (0)
Not all progressive metabolic diseases on PET are equal in patients with relapsed or refractory sarcoma (2013) (0)
PET-CT in Clinical Practice : Experience in 1500 Patients (2002) (0)
FDG PET/CT-based Response Assessment in Malignancies. (2023) (0)
Voxelized Dose--FDG-PET Response in HDR Brachytherapy of Rectal Cancer. (2013) (0)
ranulocyte colony-stimulating factor (G-CSF) is a glycoprotein hormone that primarily regulates proliferation and differentiation of granulocyte precursors (1â€”3).Human G-CSF, which is produced by recombinant deoxyribonucleic (2006) (0)
Brown adipose tissue (BAT) lipid content, a dynamic parameter potentially confounding measurements of BAT radiotracer targeting (2014) (0)
Time course of FDG uptake into brown adipose tissue following single and repeated {beta}-3 agonist administrations - Effect of washout period (2014) (0)
Pilot study of SGN-15 immunoconjugate with docetaxel as first line therapy for NSCLC with PET assessment of response (2005) (0)
Pelvic radionuclide angiography in the diagnosis of gastrointestinal bleeding. (1984) (0)
Value of PET/CT fusion imaging versus conventional CT scans in the staging and management of patients with malignant pleural mesothelioma (2007) (0)
Gender-specific effect of different lean body mass formulations on hepatic SUV: Paradoxical low values in morbidly obese women (2013) (0)
Auto-PERCIST™: A semi-automated system for the quantitative assessment of FDG PET images by PERCIST 1.0 (2013) (0)
Utility of anatometabolic imaging for radiation treatment planning for lung cancer (2000) (0)
Case Report: Brown Fat Accumulation of Tc-99m Macroaggregated Albumin in a Lung Perfusion Study in a Patient With Multiple Lung Arteriovenous Malformations and Right-to-Left Shunting (2015) (0)
Imaging Melanoma (2019) (0)
DEVELOPMENT OF A STANDARD INPUT FUNCTION FOR PATLAK TUMOR IMAGING (1994) (0)
Head and Neck Cancer: Detection of Recurrence with Three-dimensional Principal Components Analysis at (1999) (0)
Overview of oncologic applications of PET and PET/CT (2005) (0)
Gallbladder visualization on hepatic artery perfusion scintigraphy. (1987) (0)
Isotype Switch VariantAnti-Idiotype Monoclonal Antibodies: Comparative Radiolabelingand In Vitro Binding (1989) (0)
TSH is a growth-promoting factor for porcine thyroid cells (1986) (0)
Phase II study of preemptive high dose chemotherapy and autologous stem cell transplantation for lymphoma based on early FDG-PET scanning. (2006) (0)
Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model. (2023) (0)
Angular Sampling Necessary for Clinical SPECT (2006) (0)
ETAC reagents: A new class of sulfhydryl site-specific radiolabeling probes for antibodies (1991) (0)
Reproducibility of "glucose corrected" hepatic SUL compared to uncorrected hepatic SUL in baseline and follow-up studies (2011) (0)
ROC analysis of varying PET metrics to predict survival in patients with Ewing sarcoma family of tumor (2013) (0)
Assessing the agreement of PET/CT metrics obtained using different software platforms (2013) (0)
Exercise capacity and body mass index are more important than diabetes in the prediction of high risk markers on myocardial perfusion imaging (2009) (0)
Antitumor effects of arsenic trioxide alone and in combination with pro-oxidants, Akt-inhibitors and sirolimus on transformed thyroid cells in vitro (2007) (0)
The pyramidal lobe — a helpful criterion in the differential diagnosis of thyroid diseases (1989) (0)
Hypoxia marker pimonidazole accumulation and glucose transporter-1 expression are strongly correlated in rodent breast cancers (2010) (0)
Moving NaI(Tl) gamma counters towards improved quantitative accuracy for PET applications using traceable calibration sources (2014) (0)
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. (2023) (0)
Atlas of PET/CT with SPECT/CT, with DVD (2009) (0)
Evaluation of Candidate Theranostics for 227Th/89Zr Paired Radioimmunotherapy of Lymphoma. (2023) (0)
Comparative biodistribution of 18F-fluoro-2-deoxy-D-glucose (FDG) and eight radiolabeled amino acids in a rodent model of breast cancer (2008) (0)
Abundance of hexokinase 1 (HK1) mRNA in hematological cancer cell lines appears better correlated with their doubling times than Ki67 and PCNA (2014) (0)
PARP inhibitors in combination with external beam and radioimmunotherapy in aggressive lymphoma (2010) (0)
Noise considerations for tumor response monitoring with FDG PET (2011) (0)
Transcriptome foundations of high FDG uptake in lung cancer (2009) (0)
Don't forget MERiT. (1996) (0)
Tracer kinetic model and dosimetry for orally administered 18F-FDG (2012) (0)
Normal hepatic SUL measured over a wide range of time points post FDG injection - Potential application in background correction in quantitative PET (2011) (0)
Other Applications of PET (2005) (0)
Variation in PET-CT methodology at academic centers (2009) (0)
[Hereditary thyroxine-binding globulin deficiency combined with hypertrophic obstructive cardiomyopathy]. (1978) (0)
Individualizing Cancer Therapies Using PET Imaging (2007) (0)
Comparison of Bexxar(R) (tositumomab and iodine I-131 tositumomab) and Zevalin(R) (Y-90 ibritumomab tiuxetan) in a single center clinical practice setting (2006) (0)
Metrology s tandards for Quantitative imaging (2015) (0)
Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen) (2010) (0)
Impact of renal function on average hepatic standardized uptake value (SUVavg) (2011) (0)
Society of Nuclear Medicine (2001) (0)
Comparative analysis of 18F-FDG and 18F-NaF PET/CT in detecting osseous metastases in breast cancer (2012) (0)
Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model (2022) (0)
Prognostic value of F18-FDG PET/CT and autoimmune antibody panels in patients with suspected paraneoplastic syndromes (2015) (0)
223Ra- Dichloride therapy for castrate-resistant prostate cancer osseous metastases (2014) (0)
NI-39INITIAL EVALUATION OF AN ADENOSINE RECEPTOR AGONIST'S ABILITY TO TRANSIENTLY DISRUPT THE BLOOD BRAIN BARRIER (BBB) IN PATIENTS WITH IN NORMAL BRAINS (2014) (0)
Dose esclation in radioimmunotherapy based on projected whole body dose (1994) (0)
Clinical significance of iodine-123 metaiodobenzylguanidine cardiac imaging. (2009) (0)
HYPOXIA LIMITS THE CARDIAC REGENERATIVE POTENTIAL OF HYPOXIA-INDUCIBLE- FACTOR-1ALPHA TRANSDUCED CARDIAC-DERIVED STEM CELLS (2010) (0)
Prospective Absorbed Dose-Based Treatment Planning in Y-90 Microsphere Therapy for Liver Cancer Using Tc-99m: A Feasibility Study (2015) (0)
FDG volumetric parameters and patient outcome in recurrent head and neck squamous cell cancer patients after definitive chemoradiotherapy (2013) (0)
An ion-implanted-silicon detector based probe for the intraoperative detection of beta emitters (1996) (0)
Bias reduction in correlation of radiation-absorbed dose with response. (2004) (0)
Initial experience monitoring response of Hodgkin's lymphoma to radioimmunotherapy with FDG PET/CT (2010) (0)
Business models for academic medical center cyclotron operations. (2005) (0)
Assessment of quantitative FDG PET parameters for prognosis in pediatric Hodgkin lymphoma (2013) (0)
Granulocyte function after labeling with monoclonal antigranulocyte antibodies (1985) (0)
Influence of insulin, proinsulin, IGF-I and TRH on the growth and iodide uptake of cultured porcine thyroid cells (1989) (0)
The inverse spatial and quantitative relationships of the voltage sensor 14C-FBnTP (fluorobenzyltriphenylphosphonium) and spontaneous apoptotic cell death in rodent syngeneic mammary tumors (2011) (0)
Initial evaluation of the applicability of PET response criteria in solid tumors (PERCIST 1.0) (2010) (0)
SNMMI Newsline. (2020) (0)
The effect of tumor location with respect to the image matrix in 18F-FDG PET/CT (2015) (0)
Intratumoral distribution of GLUTs and hexokinase II in rodent breast cancer (2011) (0)
Comparison of quantitative NaF PET bone scan findings to quantitative CT density (Hounsfield units) in malignant NaF-avid bone lesions (2012) (0)
PET Diagnosis and Response Monitoring in Oncology (2021) (0)
BAT activation in diabetic rats undergoing treatment with CL316, 243 and cold exposure (2012) (0)
Uncertainty method and values for whole organ and tumor absorbed doses calculated in 3DRD for 90Y PET/CT dosimetry in selective internal radiation therapy (SIRT) (2012) (0)
Issues and Challenges in Applications of Artificial Intelligence to Nuclear Medicine - The Bethesda Report (AI Summit 2022) (2022) (0)
Performance of a PERCIST 1.0 based CAD system in the evaluation of head and neck cancer (2011) (0)
Improved radioimmunolocalization of human tumor xenografts following subcutaneous delivery of monoclonal antibodies (2004) (0)
Monoclonal antibody (5G6.4) against ovarian carcinoma shows inhibition of in vitro colony formation. (1987) (0)
Department of radiology (1943) (0)
Interpreting Baseline and Follow-Up 18-Fluorodeoxyglucose-PET Total Lesion Glycolysis in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer (2014) (0)
Non-invasive PET imaging of brown adipose tissue (BAT) and quantification of the kinetics of the thermogenic function using the voltage sensor 18F-FBnTP (fluorobenzyl triphenyl phosphonium) (2011) (0)
Abstract 1080: Myocardial Substrate Determines Acute Cardiac Retention and Lung Biodistribution of Intramyocardially Injected Cardiac-Derived Stem Cells - A PET/CT Experimental Study (2008) (0)
Low-dose propanolol (LDP) is effective in suppressing FDG brown adipose tissue (BAT) uptake in pediatric patients: Qualitative and quantitative analyses (2011) (0)
Head and neck PET/CT: Therapy response interpretation criteria ('Hopkins criteria') (2014) (0)
Respiratory-gated PET/CT vs delayed images in the quantitiative evaluation of lower pulmonary and hepatic lesions in clinical practice (2011) (0)
Correlation of metabolic activity on FDG PET/CT to the size of benign and malignant lesions in patients with neurofibromatosis type 1 (NF1) (2013) (0)
Molecular comparison of glycolytic and DNA synthesis pathways in human breast cancer before and after treatment with an aromatase inhibitor: Implications for FDG and FLT PET (2013) (0)
Optimization of noninvasive parametric imaging in dynamic whole-body FDG PET-CT (2013) (0)
Coronary calcium scores in patients with normal myocardial perfusion (2009) (0)
Prior rituximab exposure does not affect response to radioimmunotherapy for non-Hodgkin's lymphoma (2009) (0)
The Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer Abstract Form For Office Use (2019) (0)
Abstract 5280: Positron Emission Tomography (PET) for In Vivo Quantification and Optimization of Acute Cell Retention after Intramyocardial Cardiac-Derived Stem Cell Delivery (2008) (0)
Imaging (2020) (0)
Evaluation of hypoxanthine for malaria imaging (2009) (0)
Effect of body weight on standardized uptake values on 18F-DCFPyL (PSMA) PET/CT in patients with prostate cancer. (2023) (0)
The role of FDG PET/CT in the evaluation of patients with T1 and T2 (early stage) head and neck squamous cell carcinoma (2014) (0)
Evaluating quality in practice: A primer on peer review for nuclear medicine physicians (2013) (0)
Genetic labeling of cardiac stem cells for in vivo monitoring of engraftment in ischemic myocardium (2008) (0)
Findings on initial staging FDG PET/CT in newly-diagnosed pediatric Hodgkin's lymphoma with comparison to physical exam and diagnostic CT (2008) (0)
RESEARCH A RTICLE Synthesis and Biodistribution of ( 11 C)Adenosine 5 0 -Monophosphate (( 11 C)AMP) (2005) (0)
Efficacy of FDG PET/CT in patients with recurrent pancreatic cancer (2011) (0)
Inguinal lymph nodes in patients undergoing clinical C-11 Acetate PET/CT for prostate cancer (2010) (0)
Molecular pathway analysis of glycolysis and acetate accumulation in hepatocellular carcinoma - Rationale for PET/CT imaging tracer selection (2012) (0)
Change in hottest tumor location following treatment on FDG PET in patients with Ewing sarcoma: A marker of poor prognosis (2013) (0)
Transcriptome foundations of choline and acetate uptake in prostate cancer (2009) (0)
Cross-calibration of gamma counters and PET scanners using Ge-68/Ga-68 (2011) (0)
New initiatives in research and discovery (2018) (0)
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification (2022) (0)
Tissue density heterogeneities influence and simple density correction method for 3D dosimetry in the abdominal region (2012) (0)
HIPP: A heterogeneity and irregularity parameter based on PERCIST for FDG PET imaging with prognostic value (2013) (0)
P-972 Pilot study of SGN-15 immunoconjugate with docetaxel as firstline therapy for NSCLC with FDG-PET assessment of response (2005) (0)
[Peritoneal dialysis in thyroxine poisoning?]. (1973) (0)
Development of a new correction to SUV in PET based on measurement of adipose/lean tissue content in a single CT slice (2013) (0)
Characterizing the repeatability of oncology PET standardized uptake values (2013) (0)
Diagnostic value of FDG PET/CT imaging in monitoring patients with endometrial carcinoma (2013) (0)
A systematic approach to PET/CT interpretation and reporting in oncology (2009) (0)
Assessment of reproducibility in quantitative FDG PET and CT measurements of tumor response to therapy (2009) (0)
Validation of diagnostic software. (1986) (0)
Treatment of cystic grade IV astrocytoma and crainopharyngioma with radioactive phosphorus - A preliminary report (1985) (0)
225Ac imaging of NK1-targeted {alpha}-particle for glioblastoma radiotherapy (2014) (0)
Glucose Transportersand FDG Uptake in Untreated PrimaryHuman Non-Small Cell Lung Cancer (1999) (0)
Fully-automated PET quality assurance using Fourier and statistical methods (2008) (0)
Gene profiles of thymidine de novo and salvage pathways in 136 patients raises question of using FLT for imaging prostate cancer (2015) (0)
The detection and clinical significance of extrahepatic abdominal perfusion (EHP) using Tc-99m MAA hepatic arterial perfusion scintigraphy (HAPS) (1984) (0)
"A Positron-emitting internal marker for identification of normal tissue by positron emission tomography: Phantom studies and validation in Patients," (Molecular Imaging and Biology (2003) vol. 5 (2) 79-85)) (2003) (0)
Relationship of age, FDG dose, body morphology, and dimensional scanner acquisition mode to image noise as measured by the coefficient of variation of normal hepatic SUL (2013) (0)
Thymidine kinase 1 (TK1) message levels in colon cancer cell lines are better correlated with cancer cell doubling times than PCNA or transporter message levels (2014) (0)
Abstract 18277: Bioadhesive and Biodegradable Hyaluronic Acid-Serum Hydrogel Promotes Cardiac Regeneration (2013) (0)
In vitro characterization of nucleoside transporter mediated uptake and intracellular accumulation of [3H]AMP in tumor cells (2006) (0)
Three monoclonal antibodies (mab) to antigens associated with small cell carcinoma of the lung (sclc) (1985) (0)
The FAZA/FDG uptake ratio: Potential index of tumor hypoxia? (2007) (0)
Effects of pegfilgrastim (Neulasta(R)) on FDG biodistribution in a rat tumor model (2006) (0)
Phase II single-arm trial comparing the use of FLT PET/CT to standard computed tomography to assess the treatment response of neoadjuvant docetaxel and cisplatin in stage IB-IIIA resectable non-small cell lung cancer (2014) (0)
Relationship of age, gender and body morphometry to normal hepatic SUL: Paradoxically low hepatic SUL in morbidly obese women (2011) (0)
Abstract 14903: SPECT-CT and Bioluminescence Imaging Reveal the Important Contribution of Cellular Bioenergetics on the Molecular Imaging Signal from Stem Cells Expressing Luciferase and The Sodium-Iodide Symporter (2012) (0)
Reproducibility of liver SULmean on two different FDG PET/CT scans (2013) (0)
Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin) (1992) (0)
Change in hottest tumor location on FDG PET in non-CMR patients with NHL: A marker of good prognosis? (2013) (0)
Use of radioimmunotherapy in the United States of America: Opinions of nuclear physicians and radiation oncologists (2010) (0)
Monoclonal antibody scintigraphy of human squamous cell carcinoma xenografts (1985) (0)
Tumor uptake of 14C-thymidine in rodent breast cancer: Interrelationship with perfusion, hypoxia, glycolysis and glucose transporter expression (2010) (0)
Intratumoral co-distribution of 18F-FDG, hypoxia and apoptosis (2011) (0)
Clinical Trials Design, Development, and Outreach Working Group (2014) (0)
Semi-quantitative assessment of dual time point whole body FDG PET/CT imaging in patients with pancreatic cancer (2011) (0)
FDG PET/CT for monitoring response of non-Hodgkin's lymphoma to radioimmunotherapy (2007) (0)
In vitro study of PET tumor tracers at normal and elevated media glucose levels (1996) (0)
Performance of FDG PET/CT in the initial staging of endometrial cancer (2013) (0)
SNMMI Leadership Update: New Initiatives in Research and Discovery. (2018) (0)
Is the number of target lesions evaluated on FDG PET important in assessing treatment response (2009) (0)
Comparison of lung cancer genomic profiles for glycolysis versus proliferation radiotracers (2012) (0)
Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data (2001) (0)
SNMMI Leadership Update: Putting Patients First: A Year in Review. (2022) (0)
Diagnostic performance of FDG PET/CT in patients with endometrial cancer (2013) (0)
Accuracy of image fusion of normal upper abdominal organs visualized with In111 Octreotide SPECT/CT using a 16 slice CT/SPECT scanner (2007) (0)
Orally administered 18F-FDG: Human biodistribution and dosimetry (2014) (0)
Iodide supplementation: 200 micrograms daily or 1,500 micrograms weekly? (1998) (0)
Treatment response by FDG PET/CT in patients with non-Hodgkin’s lymphoma treated with radioimmunotherapy: Link to survival (2013) (0)
Unintentional intraluminal small bowel catheter placement detected by Tc-99m SC scan obtained before planned intraperitoneal phosphorus-32 therapy. (1993) (0)
Comparison of 99mTc MAA and 90Y activity distribution in patients with hepatocellular carcinoma (HCC) treated with glass microspheres (MS) transarterial radioembolization (TARE) (2015) (0)
Pivotal S tudy o f I odine I 1 31 T ositumomab f or Chemotherapy-Ref ractory L ow-Grade o r T ransformed Low-Grade B -Cell N on-Hodgkin's L ymphomas (2001) (0)
The use of vasoconstrictors to improve the tumor to non-tumor blood flow ratio (T/NT) in intraarterial chemotherapy (IAC) of head and neck cancer (H and N CA) (1984) (0)
Machine learning based dual tracer FDG+68Ga-DOTATATE PET imaging for the diagnosis of neuroendocrine tumor (2020) (0)
The differential response of fluorobenzyl triphenyl phosphonium (FBnTP) and FDG upon activation of brown adipose tissue (BAT) thermogenesis (2010) (0)
[Displacement of thyroid hormones from the link of serum proteins and heart mitochondria through drugs]. (1975) (0)
NIMG-35RESULTS OF EXPLORATORY 18F-FLT PET IMAGING IN TEN RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH THE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER MIBEFRADIL FOLLOWED BY TEMOZOLOMIDE (ABTC TRIAL 1101) (2015) (0)
Potential for augmentation of FDG uptake in tumor cells in-vitro with A3 adenosine receptor stimulation (2007) (0)
Localization of radiolabeled anti-DNA monoclonal antibodies in murine systemic lupus erythematosus (SLE) (1984) (0)
Between application differences in the calculation of standardized uptake values (SUV) in PET-CT (2008) (0)
Quantifying metabolic tumor response to therapy: The influence of image noise on maximum and mean SUV (2008) (0)
Functional mitochondria detected by 18F-FBnTP is a prominent trait of tumor cell proliferation in vivo (2011) (0)
Radioimmunotherapy.org: A web 2.0-based online community (2009) (0)
Ephedrine administered directly into brown adipose tissue markedly reduces FDG accumulation (2008) (0)
Radioresistant Rag2-IL2rg (R2G2) mice demonstrate position-dependent bioluminescent tumor signal and increased lethality compared to severe combined immunodeficient (SCID) mice in a disseminated lymphoma model. (2019) (0)
Initial experience with tositumomab and iodine I 131 tositumomab for treatment of relapsed/refractory Hodgkin lymphoma (2011) (0)
Time course of FDG uptake into brown adipose tissue activated by the beta3-adrenoceptor agonist CL316243 (2009) (0)
In vivo pre-clinical PET/CT evaluation of [11C]adenosine 5'-monophosphate as a novel PET radiotracer for imaging tumor nucleoside transporters (2006) (0)
Clinical utility of whole body scan in addition to cardiac FDG PET in the evaluation of active cardiac sarcoidosis (2012) (0)
Is a "yes"-"no" answer adequate in reporting nuclear medicine diagnostic imaging results? (2008) (0)
A positron-emitting internal marker for identification of tissues by PET: Phantom studies (2000) (0)
Commentary (Wahl): Diagnostic Use of Radiolabeled Antibodies for Cancer (1995) (0)
Correlation of K-ras mutation with FDG uptake in lung cancer (2010) (0)
Disulilde Bond-targeted Radiolabeling: Tumor Specificity of a Streptavidin- biotinylated Monoclonal Antibody Complex1 (2006) (0)
Quantitative analysis of PET/CT in bronchioloalveolar carcinoma (2008) (0)
Practical PERCIST 1.0 (2013) (0)
Procedure for establishing the optimum radiation dose for the radiopharmaceutical treatment of a disease. (1996) (0)
Radiomic Phenotype of Activated Brown Fat on FDG PET (2018) (0)
Stability of SPECT uptake value ("SPECT-UV") in normal abdominal organs for 111In-pentetreotide imaging (2014) (0)
Comparison of acetate and L-methionine as potential pancreatic imaging agents: Pre-clinical studies (2008) (0)
18 F-FDGPET/CTforMonitoringtheResponse of Lymphoma to Radioimmunotherapy (2009) (0)
A method for the determination of the optimum radiation dose for treatment of disease radiofamaceutisk (1996) (0)
Radioiodine therapy in pediatric and adolescence with well differentiated thyroid cancer (2011) (0)
Radiolabeled monoclonal antibodies (for the radiology administrator). (1992) (0)
Patient discharge instructions for I-131 Bexxar therapy vs. I-131 sodium iodide therapy (2009) (0)
'Double right atrium' demonstrated by radionuclide ventriculography in cardiac transplantation. (1990) (0)
Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101). (2013) (0)
Positron emission tomography in chest diseases (2011) (0)
Introdcution to Technical Considerations for PET/CT and SPECT/CT (2008) (0)
[Familial coincidence of hypertrophic cardiomyopathies and thyroxine-binding globulin deficiency (athyropexinemia) (author's transl)]. (1978) (0)
Ensuring Quality and Safety in Nuclear Medicine Imaging and Therapy. (2022) (0)
[Influence of various drugs on the adsorption of thyroid hormones to liver mitochondria (author's transl)]. (1974) (0)
AMP and FDG lung uptake in a mouse model of cystic fibrosis (2008) (0)
Issues using volumetric image quantification tools across clinical workstations (2010) (0)
A kinetic model of patient platelets after radioimmunotherapy (2008) (0)
Positron emission tomography. (1995) (0)
PET begins to prove itself in cancer care. (1996) (0)
Potentiation of right ventricular function at a reduced workload: a potential pitfall in assessing right ventricular function by exercise radionuclide ventriculography. (1987) (0)
Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric (2007) (0)
Interaction between thyrotrophin and tissue growth factors on the morphology of cultured thyroid cells (1988) (0)
Changes in FDG-PET SUV correlate with voxel absorbed dose in HDR brachytherapy of rectal cancer (2012) (0)
18F-FDG-PET-CT evaluation of melanoma progression versus non-progression using PERCIST 1.0 (2012) (0)
Inter-observer agreement of functional imaging of the paranasal sinuses with FDG PET (2010) (0)
Different transcriptome responses in brown fat following exposure to a {beta}3 agonist or cold temperature (2014) (0)
Delineation of viable tumor volume using FDG-PET validated with macroscopic sectioning of pathological specimens (2013) (0)
Serial PET/CT in the evaluation of response to neoadjuvant therapy in patients with newly diagnosed rectal carcinoma (2006) (0)
Quantitative Imaging in Oncologic PET (2021) (0)
Pediatric radiopharmaceutical dose reduction in nuclear medicine imaging (2013) (0)
Dosimetry for Cystic-Type Tumors—Reply (1986) (0)
Kinetics of the thyroid hormone during pertioneal dialysis (1974) (0)
Targeting of PD-L1 in mouse xenograft tumors by 89Zr-atezolizumab is specific but strongly mass-dependent (2019) (0)
Atlas of PET/CT with SPECT/CT (2008) (0)
Thrombokinaseaktivitt von Schilddrsenextrakten@@@Thromboplastin activity of extracts of human thyroid glands (1975) (0)
Profound morphological changes are associated with high FDG uptake in brown adipose tissue as observed in TEM images (2010) (0)
Single photon emission computed tomography/computed tomography (SPECT/CT) in sentinel lymph node imaging in head and neck cancer (2014) (0)
SNMMI Leadership Update: Advancing Radiopharmaceutical Therapy. (2021) (0)
A method for determining the optimal dose of radiation for radiation therapy of diseases (1996) (0)
FDG PET/CT Imaging: Clinical Uses and Opportunities (2008) (0)
SPECT-CT/organ dosimetry: Phase I dose-escalation trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with stem cell transplantation (ASCT) in NHL (2008) (0)
Cardiac PET-CT misregistration causes significant changes in myocardial flow reserve (MFR) (2012) (0)
Head and neck carcinomas (2014) (0)
ROC-analysis of quantitative early and delayed PET SUL in malignant peripheral nerve sheath tumors (MPNST) versus neurofibroma (BT) (2012) (0)
Feasibility and potential limitations of PERCIST 1.0 criteria for comparison of sequential studies in routine clinical practice (2011) (0)
[A model for the adsorptive distribution of thyroid hormone in the cell (author's transl)]. (1978) (0)
PET and SPECT molecular imaging as biomarkers in cancer therapeutic trials (2010) (0)
A Case-Based Approach to PET/CT in Oncology: Breast (2012) (0)
Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”) (2014) (0)
FDG PET/CT imaging in urinary bladder cancer: A retrospective analysis (2009) (0)
CT in clinical PET/CT in the community: Evaluation of the CT component (2011) (0)
Methodology for radiobiological optimization of combination radiopharmaceutical therapy (RPT) (2013) (0)
SNMMI to Host Summits on Artificial Intelligence and Patient Access. (2022) (0)
Tissue uptake and effects of the metabolic inhibitor 3-bromopyruvate on fluorodeoxyglucose in vivo (2008) (0)
Carcinoma of the breast (2015) (0)
Clinical Trials Design and Development Working Group (2014) (0)
Brown Adipose Tissue: A Protective Mechanism Against “Preprediabetes”? (2022) (0)
SU-E-J-270: Study of PET Response to HDR Brachytherapy of Rectal Cancer. (2014) (0)
Average versus summed SUV for assessing metabolic tumor response to therapy (2007) (0)
[Medical measures in nuclear engineering accidents. Uses and risks of iodine prophylaxis]. (1981) (0)
Effects of serum glucose on SUL of normal liver, a dynamic glucose metabolism organ (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard L Wahl?

Richard L Wahl is affiliated with the following schools:

Richard L Wahl's Academic­Influence.com Rankings

Richard L Wahl's Degrees

Similar Degrees You Can Earn

Why Is Richard L Wahl Influential?

Richard L Wahl's Published Works

Published Works

What Schools Are Affiliated With Richard L Wahl?

Richard L Wahl's AcademicInfluence.com Rankings